HAI Book 2025 - Flipbook - Page 540
Pezzoli, Stefania
119
Evaluating the effect of APOE genotype in real-world clinical
settings: results from the IDEAS-ANGI study
Stefania Pezzoli1, Caroline Jonson1, Ganna Blazhenets1, Daniel Schonhaut1, Jhony M. Perez1,
Alexis Oddi1, Ale Castruita1, Kaitlin B. Casaletto1, Lucy Hanna2, Andrew March3, Constantine
Gatsonis2,4, Maria C. Carrillo5, Tatiana M. Foroud6, Renaud La Joie1, Jennifer S. Yokoyama1, Gil
D. Rabinovici1
1
Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, US
Center for Statistical Sciences, Brown University School of Public Health, Providence, RI, US
3
Center for Research and Innovation, American College of Radiology, Reston, VA, US
4
Department of Biostatistics, Brown University School of Public Health, Providence, RI, US
5
Alzheimer’s Association, Chicago, IL, US
6
Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, US
2
Background: Real-world data about the clinical utility of APOE genotype in memory care are lacking. The ANGI
study analyzed DNA from a subset of IDEAS participants. We leveraged this large dataset to assess the predictive
value of APOE genotype in determining amyloid status and burden in real-world memory care.
Methods: 1637 Medicare beneficiaries with cognitive impairment enrolled in ANGI-IDEAS were included. Amyloid
PET positivity was determined using (a) local community visual reads and (b) a Centiloid threshold of 24.4.
Centiloids were calculated using a PET-only pipeline in a subset of 1149 participants. Logistic regression assessed
the odds of amyloid positivity, while ANCOVA investigated differences in global amyloid burden, measured in
Centiloids, adjusting for demographic and clinical characteristics.
Results: Demographics and clinical features are shown in Table 1. Among the total sample, 38% were APOE4
heterozygotes and 10% were homozygotes. Compared to APOE3/3, APOE3/4 and APOE4/4 carriers showed higher
dementia rates (p
